146 related articles for article (PubMed ID: 29766657)
1. Drug-drug interaction and doping: Effect of non-prohibited drugs on the urinary excretion profile of methandienone.
Mazzarino M; Khevenhüller-Metsch FL; Fiacco I; Parr MK; de la Torre X; Botrè F
Drug Test Anal; 2018 Oct; 10(10):1554-1565. PubMed ID: 29766657
[TBL] [Abstract][Full Text] [Related]
2. Effect of non-prohibited drugs on the phase II metabolic profile of morphine. An in vitro investigation for doping control purposes.
Ambrosio G; de la Torre X; Mazzarino M; Parr MK; Botrè F
Drug Test Anal; 2018 Jun; 10(6):984-994. PubMed ID: 29172026
[TBL] [Abstract][Full Text] [Related]
3. uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study.
Lootens L; Meuleman P; Pozo OJ; Van Eenoo P; Leroux-Roels G; Delbeke FT
Clin Chem; 2009 Oct; 55(10):1783-93. PubMed ID: 19643840
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interaction and doping, part 2: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of stanozolol.
Mazzarino M; de la Torre X; Fiacco I; Botrè F
Drug Test Anal; 2014 Oct; 6(10):969-77. PubMed ID: 24535830
[TBL] [Abstract][Full Text] [Related]
5. Efficient approach for the detection and identification of new androgenic metabolites by applying SRM GC-CI-MS/MS: a methandienone case study.
Polet M; Van Gansbeke W; Van Eenoo P; Deventer K
J Mass Spectrom; 2016 Jul; 51(7):524-34. PubMed ID: 27434811
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug interaction and doping, part 1: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of toremifene.
Mazzarino M; de la Torre X; Fiacco I; Palermo A; Botrè F
Drug Test Anal; 2014 May; 6(5):482-91. PubMed ID: 24431005
[TBL] [Abstract][Full Text] [Related]
7. Detection of urinary metabolites common to structurally related 17alpha-alkyl anabolic steroids in horses and application to doping tests in racehorses: methandienone, methandriol, and oxymetholone.
Yamada M; Aramaki S; Kurosawa M; Saito K; Nakazawa H
J Anal Toxicol; 2008 Jun; 32(5):387-91. PubMed ID: 18544225
[TBL] [Abstract][Full Text] [Related]
8. Sulfate metabolites as alternative markers for the detection of 4-chlorometandienone misuse in doping control.
Balcells G; Gómez C; Garrostas L; Pozo ÓJ; Ventura R
Drug Test Anal; 2017 Jul; 9(7):983-993. PubMed ID: 27686240
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of the effects of anti-fungals, benzodiazepines and non-steroidal anti-inflammatory drugs on the glucuronidation of 19-norandrosterone: implications on doping control analysis.
Palermo A; Alessi B; Botrè F; de la Torre X; Fiacco I; Mazzarino M
Drug Test Anal; 2016 Sep; 8(9):930-9. PubMed ID: 26480899
[TBL] [Abstract][Full Text] [Related]
10. Combination of liquid-chromatography tandem mass spectrometry in different scan modes with human and chimeric mouse urine for the study of steroid metabolism.
Pozo OJ; Lootens L; Van Eenoo P; Deventer K; Meuleman P; Leroux-Roels G; Parr MK; Schänzer W; Delbeke FT
Drug Test Anal; 2009 Nov; 1(11-12):554-67. PubMed ID: 20355172
[TBL] [Abstract][Full Text] [Related]
11. A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009.
Mazzarino M; Rizzato N; Stacchini C; de la Torre X; Botrè F
Drug Test Anal; 2018 Nov; 10(11-12):1670-1681. PubMed ID: 30395700
[TBL] [Abstract][Full Text] [Related]
12. Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination - insights from metandienone metabolism.
Parr MK; Zöllner A; Fusshöller G; Opfermann G; Schlörer N; Zorio M; Bureik M; Schänzer W
Toxicol Lett; 2012 Sep; 213(3):381-91. PubMed ID: 22885098
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the phase I and phase II metabolic profile of tolvaptan by in vitro studies and liquid chromatography-mass spectrometry profiling: Relevance to doping control analysis.
Mazzarino M; Buccilli V; de la Torre X; Fiacco I; Palermo A; Ughi D; Botrè F
J Pharm Biomed Anal; 2017 Oct; 145():555-568. PubMed ID: 28759864
[TBL] [Abstract][Full Text] [Related]
14. Analysis of anabolic androgenic steroids as sulfate conjugates using high performance liquid chromatography coupled to tandem mass spectrometry.
Rzeppa S; Heinrich G; Hemmersbach P
Drug Test Anal; 2015; 7(11-12):1030-9. PubMed ID: 26472592
[TBL] [Abstract][Full Text] [Related]
15. LC-MS/MS detection of unaltered glucuronoconjugated metabolites of metandienone.
Esquivel A; Pozo OJ; Garrostas L; Balcells G; Gómez C; Kotronoulas A; Joglar J; Ventura R
Drug Test Anal; 2017 Apr; 9(4):534-544. PubMed ID: 27237125
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine.
Schänzer W; Geyer H; Fusshöller G; Halatcheva N; Kohler M; Parr MK; Guddat S; Thomas A; Thevis M
Rapid Commun Mass Spectrom; 2006; 20(15):2252-8. PubMed ID: 16804957
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls.
Thevis M; Thomas A; Möller I; Geyer H; Dalton JT; Schänzer W
Rapid Commun Mass Spectrom; 2011 Aug; 25(15):2187-95. PubMed ID: 21710598
[TBL] [Abstract][Full Text] [Related]
18. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
Gosetti F; Mazzucco E; Gennaro MC; Marengo E
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
[TBL] [Abstract][Full Text] [Related]
19. Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine.
Sobolevsky T; Rodchenkov G
J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):121-7. PubMed ID: 22142641
[TBL] [Abstract][Full Text] [Related]
20. [Determination of doping in human urine by gas chromatography-high resolution mass spectrometry].
Xing YY; Liu X; Zhang YM; Wang XB; Xu YX
Yao Xue Xue Bao; 2012 Dec; 47(12):1667-70. PubMed ID: 23460974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
